ERBB2 and triple-negative breast carcinoma: Tumors overexpressing the epidermal growth factor receptor 2 are treated with anti HER2 monoclonal antibodies as trastuzumab and pertuzumab or with immunoconjugates as TDM1 or kinase inhibitors as lapatinib or neratinib, mostly combined [51], whereas the triple-negative breast cancer that is treated with conventional and moderately successful chemotherapies displays a poor prognosis and a high risk of relapse [52, 53].